NCT03900949View on ClinicalTrials.gov

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

August 8, 2024

Study Completion Date

December 1, 2025

Conditions
Acute Myeloid Leukemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic SCT

DRUG

Cytarabine

Given IV

DRUG

Daunorubicin Hydrochloride

Given IV

DRUG

Gemtuzumab Ozogamicin

Given IV

DRUG

Midostaurin

Given PO

Trial Locations (2)

43210

Ohio State University Comprehensive Cancer Center, Columbus

97210

Oregon Health and Science University Knight Cancer Institute - Northwest Portland, Portland

All Listed Sponsors
lead

Uma Borate

OTHER